Replies to post #102949 on Biotech Values

[DewDiligence]

A program NVS has been oddly quiet about (nothing in today’s PR or CC) is Elinogrel, the antiplatelet drug licensed from Portola. I haven’t heard anything about it since the brief mention at 2010 AHA in #msg-56742275.

Has anybody here heard anything more recently?